Physicians' Academy for Cardiovascular Education

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein - Cincinnati, OH, USA

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

Educational information

This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.


Prof. Evan Stein, LIB Therapeutics and Metabolic & Atherosclerosis Research Center, Cincinnati, OH, USA


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of new data on the novel anti-PCSK9 agent

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: